Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Antonio Palumbo, Asher Chanan-Khan, Katja Weisel...
https://pubmed.ncbi.nlm.nih.gov/27557302/Actively Recruiting
Led by PETHEMA Foundation · Updated on 2026-06-25
480
Participants Needed
68
Research Sites
104 weeks
Total Duration
The trial investigates treatment options for adults with newly diagnosed multiple myeloma who are eligible for stem cell transplantation. It is a Phase III, open-label, randomized study comparing three treatment approaches to evaluate their effectiveness in achieving minimal residual disease negativity using next-generation flow cytometry. The study aims to compare an extended VRD regimen plus early rescue intervention with two Isatuximab-containing regimens. Participants are assigned to one of three groups Arm A receives Isatuximab combined with VRD followed by autologous stem cell transplant ASCT, then consolidation and continuous treatment with Lenalidomide and monthly Isatuximab Arm B receives an extended VRD regimen with ASCT plus early rescue intervention involving Isatuximab-Iberdomide-Dexamethasone, followed by consolidation and continuous treatment with adjusted VRD cycles Arm C is treated with Isatuximab, Iberdomide, VRD, and ASCT, followed by consolidation and continuous treatment with Iberdomide and monthly Isatuximab. Each treatment phase includes induction, ASCT, consolidation, and continuous therapy lasting approximately 24 months or longer. Throughout the study, participants undergo multiple cycles of treatment with frequent dosing schedules, including intravenous infusions and oral medications. Researchers assess the primary outcome by measuring the proportion of participants who are MRD-negative after 18 cycles plus ASCT, approximately 24 months. Safety and progression-free survival are monitored over about 78 months. The study also involves bone marrow analyses, adherence tracking, and reviews of therapeutic programs up to 36 months. Participants are followed closely for treatment response and adverse events during and after therapy.
CONDITIONS
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
C
Carmen López-Carrero
R
Roberto Maldonado
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
PETHEMA Foundation
Lead Sponsor
Bristol-Myers Squibb
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 24 months or longer
Participants receive induction treatment with one of three drug combinations, followed by autologous stem cell transplant and consolidation cycles. Continuous treatment continues with assigned medications until progression or other criteria.
Regular visits for drug administration and assessments
Duration - Up to 78 months
Participants are monitored for treatment response, safety, and disease progression for up to approximately 78 months.
Periodic visits for safety and progression assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Antonio Palumbo, Asher Chanan-Khan, Katja Weisel...
https://pubmed.ncbi.nlm.nih.gov/27557302/Juan-Jose Lahuerta, Bruno Paiva, Maria-Belen Vidriales...
https://pubmed.ncbi.nlm.nih.gov/28498784/Chad C Bjorklund, Jian Kang, Michael Amatangelo...
https://pubmed.ncbi.nlm.nih.gov/31719682/A Keith Stewart, S Vincent Rajkumar, Meletios A Dimopoulos...
https://pubmed.ncbi.nlm.nih.gov/25482145/Philippe Moreau, Tamás Masszi, Norbert Grzasko...
https://pubmed.ncbi.nlm.nih.gov/27119237/Brian G M Durie, Antje Hoering, Muneer H Abidi...
https://pubmed.ncbi.nlm.nih.gov/28017406/Meletios A Dimopoulos, Albert Oriol, Hareth Nahi...
https://pubmed.ncbi.nlm.nih.gov/27705267/J Bladé, D Samson, D Reece...
https://pubmed.ncbi.nlm.nih.gov/9753033/D Zamarin, S Giralt, H Landau...
https://pubmed.ncbi.nlm.nih.gov/22890289/Shaji Kumar, Bruno Paiva, Kenneth C Anderson...
https://pubmed.ncbi.nlm.nih.gov/27511158/PETHEMA Foundation
Lead Sponsor
Bristol-Myers Squibb
Collaborating Sponsor